covid: fluvoxamine decreases hospitalization
A Brazilian study found that early treatment with fluvoxamine decreased hospitalizations among high-risk patients with documented Covid-19 (see covid fluvoxamine dec hosp lancet2021 in dropbox, or doi.org/10.1016/ S2214-109X(21)00448-4 Details: -- 741 patients were allocated to fluvoxamine and 756 to placebo in a large study (the TOGETHER trial), which also had arms testing many other potentially repurposed meds (hydoxychlorozuine, lopinavir-ritonavir, metformin, ivermectin, doxazocin, interferon lambda, with the fluvoxamine component beginning Jan 20, 2021 and ending Sept 9, 2021 -- fluvoxamine arm: 100 mg twice daily for 10 days vs placebo -- All patients had presented to a patient care setting with an acute clinical condition consistent with Covid-19 within seven days of symptom onset, were positive for SARS-CoV-2 and had at least one high risk factor for progression to severe diseas...